FindTrial
Sign In

NovoTTF-100A device

DEVICE4 trials

Sponsors

NovoCure Ltd., NRG Oncology, National Cancer Institute (NCI)

Conditions

1-5 Brain Metastases From Non-Small Cell Lung CancerAnaplastic AstrocytomaGlioblastomaGlioblastoma MultiformeGliosarcomaMGMT-Unmethylated GlioblastomaOligodendrogliomaSupratentorial Glioblastoma

Phase 2

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
NCT01755624
NovoCure Ltd.1-5 Brain Metastases From Non-Small Cell Lung Cancer
Start: 2013-01-31End: 2017-07-31Updated: 2016-09-21
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
WithdrawnNCT04105374
NRG OncologyAnaplastic Astrocytoma, Glioblastoma, Oligodendroglioma +1
Start: 2020-01-31End: 2030-11-30Updated: 2020-03-24
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
CompletedNCT04396860
National Cancer Institute (NCI)Gliosarcoma, MGMT-Unmethylated Glioblastoma
Start: 2020-09-01End: 2025-12-23Updated: 2026-03-05

Phase 3

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
CompletedNCT00916409
NovoCure Ltd.Glioblastoma Multiforme
Start: 2009-06-30End: 2017-03-31Target: 700Updated: 2017-04-10

Related Papers

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.
2025-04-23
INNV-38. 3 DAYS-ON-1 DAY-OFF FRACTIONATED USE PROTOCOL FOR IMPROVED COMPLIANCE AND PREVENTATIVE SKIN SAFETY FOR USE OF TUMOR TREATING FIELDS: PRACTICE IMPROVEMENT STRATEGY IN NEURO-ONCOLOGY
Neuro-Oncology2024-11-011 citations
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
2024-02-235 citations
CTIM-18. NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Neuro-Oncology2023-11-019 citations
QOL-15. THE PIVOTAL TRIDENT STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY WITH CHEMORADIATION, FOLLOWED BY MAINTENANCE TTFIELDS THERAPY/TEMOZOLOMIDE (TMZ), IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Neuro-Oncology2023-11-01
TUMOUR TREATING FIELDS (TTFIELDS) THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: A META-ANALYSIS AND SYSTEMATIC REVIEW OF REAL-WORLD SURVIVAL DATA
Neuro-Oncology2023-09-16
PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Neuro-Oncology2023-09-017 citations
P11.25.A TUMOR TREATING FIELDS (TTFIELDS) REAL-WORLD EXPERIENCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OVERALL SURVIVAL
Neuro-Oncology2023-09-01
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
LMAP-12 TUMOR TREATING FIELDS (TTFIELDS) REAL-WORLD EXPERIENCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OVERALL SURVIVAL
Neuro-Oncology Advances2023-08-01
Tumor treating fields (TTFields) therapy skin safety and prevention strategy using a fractionated schema protocol (3-days on/1-day off), effect on skin adverse events.
Journal of Clinical Oncology2023-06-012 citations
Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.
Journal of Clinical Oncology2023-06-011 citations
TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report
Brain Sciences2023-04-075 citations
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study
Japanese Journal of Clinical Oncology2023-01-1621 citations
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
2023-01-0112 citations
CTNI-28. SYSTEMATIC REVIEW OF PHASE III TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA 2005-2021
Neuro-Oncology2022-11-011 citations
Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)
Discover Oncology2022-10-1414 citations
P11.14.A Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2021
Neuro-Oncology2022-09-011 citations
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
Frontiers in Oncology2021-09-2728 citations
Efficacy of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase III EF-14 trial.
Journal of Clinical Oncology2020-05-202 citations

17 more papers not shown